Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
AI vulnerability discovery access concentration exposes least-resourced infrastructure because restricting findings to large vendors leaves regional operators and industrial systems most vulnerable
Schneier identifies a structural problem with the Project Glasswing governance model: concentrating Mythos access among approximately 50 large vendors means the best-equipped organizations receive vulnerability findings first, while smaller enterprises, regional infrastructure operators, and special
Security organizations are shifting operational models from human approval gates to autonomous systems with guardrails because threat response speed requirements eliminate human decision loops
The Sysdig analysis describes an operational model shift: 'from human-paced response to autonomous systems requiring guardrails rather than approval gates.' This is presented as one of six critical actions rated 'start this week' for organizations. The 250-CISO briefing content suggests this is not
AI-enabled offensive cyber capabilities currently favor attackers over defenders because the time to discover and weaponize vulnerabilities has compressed from weeks to overnight while organizational patch cycles have not accelerated
Anthropic frames the Mythos capability as a 'transitional period' where 'offense currently ahead of defense.' The mechanism is specific: non-experts can now ask Mythos to find remote code execution vulnerabilities overnight and receive a complete working exploit by morning—compressing what previousl
Medicaid work requirements produce 19-37% compliant worker disenrollment through documentation infrastructure failure not actual non-compliance
RWJF modeling projects that 19-37% of people who lose Medicaid coverage under work requirements will be individuals who already meet the work requirement but cannot adequately document their compliance. The mechanism is structural: proving 80 hours/month of qualifying activity requires submitting do
Psilocybin facilitator training costs ($9,359 mean, 160+ hours) create economic filtering toward already-credentialed healthcare workers despite program equity intentions, with 79% reporting moderate-to-severe financial strain and 57% already holding healthcare licenses
Oregon's psilocybin facilitator training programs charge $4,500-$12,000 tuition (mean $9,359) for 120-200 hours of coursework plus 40-hour practicum, typically spanning 8 months. Despite 50% of programs offering scholarships for equity/inclusion, 79% of trainees reported the training costs created m
Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy
Texas represents the most conservative large state in the US, yet authorized $50M for Schedule I psychedelic drug research through SB 2308 in December 2025, with potential $50M federal ARPA-H match directed by Trump executive order in April 2026. The political enabling mechanism is veteran-specific:
Federal Medicaid work requirements project 4.9-10.1M coverage losses by 2028 representing the largest single structural setback to value-based care transition in a decade
RWJF projects 4.9-10.1 million people will lose Medicaid coverage specifically from work requirements by 2028, compared to CBO's 11.8M total OBBBA Medicaid impact by 2034. This means work requirements alone account for 40-85% of projected Medicaid losses, making them the dominant coverage loss mecha
Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin
The Texas IMPACT consortium ($50M state + $50M federal) represents the largest state-sponsored psychedelic research investment targeting opioid use disorder, the highest-mortality addiction crisis (79,384 overdose deaths in 2024). MAPS Phase 2 trials demonstrate 70-75% abstinence at 1 month, and ibo
Oregon's psilocybin access gap is a demand-side cost failure, not a supply-side capacity problem — facilitators have capacity for 60,000 clients/year but only 4,500/year are being served because session costs ($1,200-3,000) are uninsured and out-of-pocket
Oregon licensed approximately 500 psilocybin facilitators by Q1 2026, each with capacity to serve ~10 clients/month (mean intended monthly clients from survey). This creates theoretical capacity of 60,000 clients/year. However, Oregon's actual utilization in Q1 2025 was 1,509 clients in 4 months, pr
Medicaid work requirement implementation precedes federal exemption guidance, creating guaranteed wrongful termination gap for medically frail populations
Nebraska's May 1, 2026 work requirement implementation exposes a critical regulatory sequencing failure: the state is enforcing 80-hour monthly activity requirements before the federal government has defined 'medically frail' — the central exemption category. Exemptions include medical issues, pregn
OCC GENIUS Act rebuttable presumption extends stablecoin yield prohibition beyond statutory text through affiliate and third-party payment restrictions
The GENIUS Act prohibits payment stablecoin issuers from paying yield directly. The OCC's implementing rule extends this prohibition through a 'rebuttable presumption' mechanism: if a PPSI contracts to pay holder yield through affiliates or third parties, it is presumed to be impermissible evasion.
AI verification limits are invoked as corporate safety arguments in government contract disputes rather than just technical research findings
Anthropic's statement explicitly argued that 'frontier AI systems are simply not reliable enough to power fully autonomous weapons'—a verification-based safety constraint used as grounds for contract refusal. This represents a novel deployment of the B4 thesis (verification degrades faster than capa
EU GPAI Code naming loss of control as mandatory systemic risk category creates formal requirement without corresponding verification infrastructure
The EU GPAI Code of Practice (July 2025) explicitly names 'loss of control' as one of four mandatory systemic risk categories requiring 'special attention' for models trained with >10^25 FLOPs. This applies to all frontier labs: Anthropic, OpenAI, Google, Meta, Mistral, xAI. The Code requires three-
EU GPAI compliance is commercially driven by market access leverage rather than enforcement threat producing minimum-viable documentation compliance
The EU's governance leverage over frontier AI labs operates through market access conditionality rather than enforcement penalties. The EU represents approximately 25% of the global AI services market, making European market access commercially essential for revenue diversification. Non-compliance w
Judicial validation that government retaliation against AI safety constraints violates the First Amendment creates a constitutional floor for AI safety corporate expression
Judge Rita Lin issued a preliminary injunction blocking the Trump administration's supply chain risk designation of Anthropic, finding likely success on three independent grounds including First Amendment retaliation. The court stated: 'Punishing Anthropic for bringing public scrutiny to the governm
Hard safety constraints backed by litigation survive government coercion where soft voluntary pledges collapse under competitive pressure
Anthropic maintained two hard safety exceptions—no mass domestic surveillance, no fully autonomous lethal weapons—for 3+ months against direct DoD coercive pressure, accepting designation as a 'Supply-Chain Risk to National Security' rather than removing the constraints. This contrasts sharply with
Judicial characterization of government AI safety retaliation as 'Orwellian' introduces a democratic legitimacy framework for AI governance that distinguishes legitimate regulation from authoritarian control
Judge Lin's characterization—'Nothing in the governing statute supports the Orwellian notion that an American company may be branded a potential adversary and saboteur of the U.S. for expressing disagreement with the government'—introduces a normative framework for evaluating AI governance legitimac
US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
CDC NCHS reports US life expectancy reached an all-time high of 79.0 years in 2024, surpassing the pre-COVID 2019 level of 78.8 years. The primary driver was a 26.2% year-over-year decline in drug overdose deaths (from 31.3 to 23.1 per 100K), with synthetic opioid deaths falling 35.6%. This represen
MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants relia
IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous ma
Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
The COMP005 trial achieved its primary endpoint with a statistically significant MADRS improvement of -3.6 points versus placebo (95% CI [-5.7, -1.5], p<0.001) at week 6 in 258 participants with treatment-resistant depression. The effect size is comparable to existing TRD augmentation strategies (ty
Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
The Executive Order issued April 18, 2026 creates three procedural accelerations for psychedelic drug development: (1) FDA National Priority Vouchers issued to Compass Pathways (COMP360 psilocybin), Usona Institute (psilocybin), and Transcend Therapeutics (methylone TSND-201) compress review timelin
Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
The Stanford ibogaine study enrolled 30 veterans with PTSD, TBI, and/or substance use disorder in an overseas clinical setting (ibogaine is Schedule I in the US). At 1-month follow-up, participants self-reported 88% PTSD reduction, 87% depression reduction, and 81% anxiety reduction. The study had n
Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that p
Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
The FDA's rejection of MDMA-assisted therapy while psilocybin trials advance reveals a critical design constraint: the intensity of psychoactive effects determines viable trial methodology. MDMA produces pronounced empathogenic and euphoric effects that make functional unblinding inevitable with ine
Page 2 of 73